Toft Group Executive Search Successfully Places Jane Wasman on Board of Directors for Rigel Pharmaceuticals in South San Francisco, CA

Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, has successfully placed Jane Wasman on the Board of Directors for Rigel Pharmaceuticals in South San Francisco, CA. Ms. Wasman is a strategic leader with over 20 years of experience in the biopharma industry working with both large multinational corporations and privately held start-ups. Her expertise includes strategic development, corporate governance, litigation, commercialization, compliance and government affairs, and operational implementation.

Ms. Wasman currently serves as President, International and General Counsel at Acorda Therapeutics. Prior to joining Acorda, Ms. Wasman held various leadership positions at Schering-Plough Corporation, including Staff Vice President and Associate General Counsel. Previously, she was an attorney at two global law firms and Associate Counsel for the U.S. Senate Veterans’ Affairs Committee. Ms. Wasman is Chair of the Board of Sellas Life Sciences and serves on the board of the non-profit NewYorkBIO.

Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School.

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate), the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel’s clinical programs include an upcoming Phase 3 study of fostamatinib in autoimmune hemolytic anemia and an ongoing Phase 1 study of R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program. In addition, Rigel has product candidates in clinical development with partners BerGenBio ASA, Daiichi Sankyo, Aclaris Therapeutics and AstraZeneca.

 About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.